Literature DB >> 1973210

Association within a family of a balanced autosomal translocation with major mental illness.

D St Clair1, D Blackwood, W Muir, A Carothers, M Walker, G Spowart, C Gosden, H J Evans.   

Abstract

282 pedigrees in the MRC Cytogenetics Registry, Edinburgh, with familial autosomal anomalies were examined for the presence of associated mental illness. In one large pedigree there were 23 cases of mental and/or behavioural disorders meeting Research Diagnostic Criteria. 34 of the 77 family members available for cytogenetic analysis carried a balanced translocation t(1:11) (q43,q21). Psychiatric diagnoses had been recorded for 16 of the 34 members with the translocation compared with only 5 of the 43 without it. The lod scores (against chance linkage of the translocation with mental illness) were greatest when the mental disorders in the phenotype were restricted to schizophrenia, schizoaffective disorder, recurrent major depression, and adolescent conduct and emotional disorders. Although the mental illness in this family may not be typical of that in the general population, the findings suggest that the q21-22 region of chromosome 11 may be a promising area to examine for genes predisposing to major mental illness.

Entities:  

Mesh:

Year:  1990        PMID: 1973210     DOI: 10.1016/0140-6736(90)91520-k

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  233 in total

1.  Genomewide genetic linkage analysis confirms the presence of susceptibility loci for schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23.

Authors:  H M Gurling; G Kalsi; J Brynjolfson; T Sigmundsson; R Sherrington; B S Mankoo; T Read; P Murphy; E Blaveri; A McQuillin; H Petursson; D Curtis
Journal:  Am J Hum Genet       Date:  2001-03       Impact factor: 11.025

2.  The chromosome 1;11 translocation provides the best evidence supporting genetic etiology for schizophrenia and bipolar affective disorders.

Authors:  Amar J S Klar
Journal:  Genetics       Date:  2002-04       Impact factor: 4.562

Review 3.  Cellular reprogramming: recent advances in modeling neurological diseases.

Authors:  Guo-Li Ming; Oliver Brüstle; Alysson Muotri; Lorenz Studer; Marius Wernig; Kimberly M Christian
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

4.  The molecular genetics of schizophrenia.

Authors:  M Owen; P McGuffin
Journal:  BMJ       Date:  1992-09-19

5.  Mapping of 262 DNA markers into 24 intervals on human chromosome 11.

Authors:  A Tanigami; T Tokino; S Takiguchi; M Mori; T Glaser; J W Park; C Jones; Y Nakamura
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

6.  The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders.

Authors:  Annie Andrieux; Paul A Salin; Muriel Vernet; Pekka Kujala; Julie Baratier; Sylvie Gory-Fauré; Christophe Bosc; Hervé Pointu; Dominique Proietto; Annie Schweitzer; Eric Denarier; Judith Klumperman; Didier Job
Journal:  Genes Dev       Date:  2002-09-15       Impact factor: 11.361

Review 7.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

8.  The schizophrenia susceptibility gene DTNBP1 modulates AMPAR synaptic transmission and plasticity in the hippocampus of juvenile DBA/2J mice.

Authors:  Ian J Orozco; Peter Koppensteiner; Ipe Ninan; Ottavio Arancio
Journal:  Mol Cell Neurosci       Date:  2013-12-07       Impact factor: 4.314

Review 9.  Clinical perspectives on the genetics of schizophrenia: a bottom-up orientation.

Authors:  Willem M A Verhoeven; Siegfried Tuinier
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 10.  Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum.

Authors:  Alexey V Shevelkin; Chinezimuzo Ihenatu; Mikhail V Pletnikov
Journal:  Rev Neurosci       Date:  2014       Impact factor: 4.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.